SHANGHAI and SUZHOU, China, Nov. 24, 2025 /PRNewswire/ — Phrontline Biopharma (“Phrontline”), a next-generation antibody–drug conjugate (ADC) company, today announced the closing of a $60 million Pre-A+ financing round. The round was led by Lapam Investment, with participation from Samsung Venture Investment Corporation (SVIC), Guofang Innovation, Hankang Venture Capital, Songqing Capital, Jifeng Ventures, and Sino Biopharmaceutical Limited. Existing shareholders — Decheng Capital, Medfine Health Fund, and C&D Emerging Investment — also participated and increased their investment in the company. This financing reflects strong investor confidence in Phrontline’s differentiated bispecific and dual-payload ADC platforms, its strategically designed pipeline, and its rapidly expanding global development capabilities. Proceeds will support advancement of the company’s clinical-stage and preclinical ADC programs, expansion of global clinical operations, and strengthening of key strategic partnerships.
Building a Leading Bispecific and Dual-Payload ADC Platform
Founded in 2022, Phrontline is among the first biotechnology companies globally to focus on bispecific antibody ADCs (BsAb-ADCs) and dual-payload ADCs. The company has built an end-to-end ADC platform spanning antibody discovery, linker–payload engineering, site-specific conjugation, and functional characterization — resulting in a proprietary, highly differentiated technology engine.
Leveraging this platform, Phrontline has designed multiple dual-target combinations and complementary payload strategies tailored to specific tumor indications and has advanced nearly ten innovative ADC programs. Among them, TJ101, a bispecific ADC targeting EGFR and B7-H3, is currently enrolling patients in parallel first-in-human clinical trials in China and the United States. Preclinical data demonstrate superior efficacy and safety relative to peer programs, positioning TJ101 as one of the leading next-generation EGFR/B7-H3 bispecific ADC candidates worldwide.
Strategic Collaborations Accelerating Global Expansion.
On October 20, 2025, Phrontline announced a global strategic collaboration with Samsung Bioepis. Under the terms of the agreement, the companies will jointly develop two next-generation bispecific, dual-payload ADC candidates with differentiated mechanisms of action, leveraging Phrontline’s proprietary BsAb and dual-payload ADC platforms.
On October 31, 2025, Phrontline entered into an exclusive license agreement with Sino Biopharmaceutical Limited for TJ101 in Mainland China and the Hong Kong SAR. Sino Biopharmaceutical will make an upfront payment of an undisclosed amount, along with potential development and commercial milestone payments and sales-based royalties. This collaboration represents a key inflection point for Phrontline’s lead asset as it transitions into accelerated global clinical development.
